{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:15:07Z","timestamp":1789730107116,"version":"4.0.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010609","name":"Gdanski Uniwersytet Medyczny","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010609","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Anhedonia constitutes one of the main symptoms of depressive episode. It correlates with suicidality and significantly effects the quality of patient's lives. Available treatments are not sufficient against this group of symptoms. Ketamine is a novel, rapid acting strategy for treatment resistant depression. Here we report the change in symptoms of anhedonia measured by Snaith-Hamilton Pleasure Scale as an effect of eight ketamine infusions as an add-on treatment in 42 patients with treatment resistant depression. We also determined the effect of this change on the severity of depressive symptoms measured by Inventory for Depression Symptomatology-Self Report 30-Item (IDS-SR 30). We have observed statistically significant decrease in the level of anhedonia during ketamine treatment. After adjusting for potential confounders we have found that significant reduction in Snaith-Hamilton Pleasure Scale (SHAPS) after each infusion and 1 week post treatment was observed only among patients who did not use benzodiazepines. The reduction in symptoms of anhedonia mediates the antidepressive effect of ketamine. The results need replication in a larger randomized placebo controlled trial.<\/jats:p>","DOI":"10.3389\/fpsyt.2021.704330","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T11:44:58Z","timestamp":1634643898000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":35,"title":["Antianhedonic Effect of Repeated Ketamine Infusions in Patients With Treatment Resistant Depression"],"prefix":"10.3389","volume":"12","author":[{"given":"Alina","family":"Wilkowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariusz Stanis\u0142aw","family":"Wiglusz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Ga\u0142uszko-Wegielnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"W\u0142odarczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wies\u0142aw Jerzy","family":"Cuba\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1177\/0269881106069938","article-title":"The other face of depression, reduced positive affect: the role of catecholamines in causation and cure","volume":"21","author":"Nutt","year":"2007","journal-title":"J Psychopharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/da.22709","article-title":"Anhedonia is associated with suicidal ideation independently of depression: a meta-analysis","volume":"35","author":"Ducasse","year":"2018","journal-title":"Depress Anxiety."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1176\/ajp.147.9.1189","article-title":"Time related predictors of suicide in major affective disorder","volume":"147","author":"Fawcett","year":"1990","journal-title":"Am J Psychiatry."},{"key":"B4","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1017\/S0033291711001905","article-title":"Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms","volume":"42","author":"Uher","year":"2012","journal-title":"Psychol Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1001\/archgenpsychiatry.2010.90","article-title":"A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression","volume":"67","author":"Diazgranados","year":"2010","journal-title":"Arch Gen Psychiatry."},{"key":"B8","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1176\/appi.ajp.2017.17040472","article-title":"The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis","volume":"175","author":"Wilkinson","year":"2018","journal-title":"Am J Psychiatry."},{"key":"B9","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/978-981-15-2902-3_5","article-title":"Synaptic modulation in the effect of ketamine","volume-title":"Ketamine From Abused Drug to- Rapid-Acting Antidepressant","author":"Okada","year":"2020"},{"key":"B10","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.bpsc.2017.04.006","article-title":"Prefrontal connectivity and glutamate transmission: relevance to depression pathophysiology and ketamine treatment","volume":"2","author":"Abdallah","year":"2017","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging."},{"key":"B11","doi-asserted-by":"publisher","first-page":"112367","DOI":"10.1016\/j.bbr.2019.112367","article-title":"Antidepressant effects of ketamine on depression-related phenotypes and dopamine dysfunction in rodent models of stress","volume":"379","author":"Rinc\u00f3n-Cort\u00e9s","year":"2020","journal-title":"Behav Brain Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/mp.2017.190","article-title":"The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders","volume":"23","author":"Kokkinou","year":"2018","journal-title":"Mol Psychiatry."},{"key":"B13","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/sj.mp.4001093","article-title":"NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia","volume":"7","author":"Kapur","year":"2002","journal-title":"Mol Psychiatry."},{"key":"B14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0022-3956(99)00031-X","article-title":"Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans","volume":"34","author":"Vollenweider","year":"2000","journal-title":"J Psychiatr Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1038\/npp.2010.74","article-title":"Blockade of astrocytic glutamate uptake in rats induces signs of anhedonia and impaired spatial memory","volume":"35","author":"Bechtholt-Gompf","year":"2010","journal-title":"Neuropsychopharmacology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1038\/tp.2014.105","article-title":"Antianhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression","volume":"4","author":"Lally","year":"2014","journal-title":"Transl. Psychiatry."},{"key":"B17","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1177\/0269881114568041","article-title":"Neural correlates of change in major depressive disorder anhedonia following open-label ketamine","volume":"29","author":"Lally","year":"2015","journal-title":"J Psychopharmacol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.jad.2020.07.083","article-title":"Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: results from the Canadian Rapid Treatment Center of Excellence","volume":"276","author":"Rodrigues","year":"2020","journal-title":"J Affect Disord."},{"key":"B19","doi-asserted-by":"publisher","first-page":"110268","DOI":"10.1016\/j.mehy.2020.110268","article-title":"Copper and anti-anhedonic effect of ketamine in treatment-resistant depression","volume":"144","author":"S\u0142upski","year":"2020","journal-title":"Med Hypotheses."},{"key":"B20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0193-953X(05)70283-5","article-title":"Definition and epidemiology of treatment-resistant depression","volume":"19","author":"Fava","year":"1996","journal-title":"Psychiatr Clin North Am."},{"key":"B21","doi-asserted-by":"publisher","first-page":"592","DOI":"10.2174\/1570159X13666150630171954","article-title":"Pharmacological approaches for treatment-resistant bipolar disorder","volume":"13","author":"Poon","year":"2015","journal-title":"Curr Neuropharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1192\/bjp.167.1.99","article-title":"A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale","volume":"167","author":"Snaith","year":"1995","journal-title":"Br J Psychiatry."},{"key":"B23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1017\/S0033291703001107","article-title":"The inventory of depressive symptomatology, clinician rating (IDS-C) and self-report (IDS-SR), and the quick inventory of depressive symptomatology, clinician rating (QIDS-C) and self-report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation","volume":"34","author":"Trivedi","year":"2004","journal-title":"Psychol Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jad.2017.04.057","article-title":"Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials","volume":"218","author":"Ballard","year":"2017","journal-title":"J Affect Disord."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1177\/0004867415590631","article-title":"Benzodiazepines may reduce the effectiveness of ketamine in the treatment of depression","volume":"49","author":"Ford","year":"2015","journal-title":"Aust N Z J Psychiatry."},{"key":"B26","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/JCP.0000000000000316","article-title":"Concomitant benzodiazepine use attenuates ketamine response: implications for large scale study design and clinical development","volume":"35","author":"Frye","year":"2015","journal-title":"J Clin Psychofarmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fpsyt.2020.00844","article-title":"The antidepressant effect of ketamine is dampened by concomitant benzodiazepine medication","volume":"28","author":"Andrashko","year":"2020","journal-title":"Front Psychiatry."},{"key":"B28","doi-asserted-by":"publisher","first-page":"112548","DOI":"10.1016\/j.bbr.2020.112548","article-title":"Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant","volume":"384","author":"Kokane","year":"2020","journal-title":"Behav Brain Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1055\/s-2007-979558","article-title":"Long-term use of benzodiazepines: tolerance, dependence and clinical problems in anxiety and mood disorders","volume":"29","author":"Michelini","year":"1996","journal-title":"Pharmacopsychiatry."},{"key":"B30","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1097\/NMD.0000000000000348","article-title":"Determinants of treatment-resistant depression: the salience of benzodiazepines","volume":"203","author":"Parker","year":"2015","journal-title":"J Nerv Ment Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/NMD.0000000000000517","article-title":"Clinical characteristics associated with treatment-resistant bipolar disorder","volume":"205","author":"Parker","year":"2017","journal-title":"J Nerv Ment Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1176\/appi.ajp.2019.19060631","article-title":"Esketamine and the need for a new type of registry for drugs with abuse potential","volume":"176","author":"McShane","year":"2019","journal-title":"Am J Psychiatry."},{"key":"B33","doi-asserted-by":"publisher","first-page":"19m12891","DOI":"10.4088\/JCP.19m12891","article-title":"Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2)","volume":"81","author":"Wajs","year":"2020","journal-title":"J Clin Psychiatry."},{"key":"B34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.euroneuro.2021.03.005","article-title":"Registry-based studies: what they can tell us, and what they cannot","volume":"45","author":"Taipale","year":"2021","journal-title":"Eur Neuropsychopharmacol."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.704330\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T11:45:14Z","timestamp":1634643914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.704330\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,18]]},"references-count":34,"alternative-id":["10.3389\/fpsyt.2021.704330"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2021.704330","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,18]]},"article-number":"704330"}}